“`html
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical firm focusing on innovative cancer immunotherapies, is poised to release topline results from its pivotal Phase 3 trial (IOB-013/KN-D18) on **August 11, 2025, at 8:30 AM ET**. The company will host a conference call and live webcast to dissect the data stemming from the trial, which is evaluating Cylembio, their investigative immune-modulatory cancer vaccine. The study pits Cylembio in combination with Merck’s blockbuster drug, KEYTRUDA® (pembrolizumab), against KEYTRUDA® alone as a first-line treatment for patients grappling with advanced melanoma.
Investors and analysts are keenly watching the trial’s outcome, as positive data could significantly impact IO Biotech’s market position and future prospects. The trial specifically targets patients with unresectable or metastatic melanoma, a patient population with considerable unmet medical needs. Management plans a live, in-depth discussion of the results as part of the scheduled event. For those unable to attend live, a replay will be accessible on the company’s official website shortly after the conclusion of the call.
IO Biotech (NASDAQ:IOBT), azienda biofarmaceutica in fase clinica, ha programmato una conference call e un webcast per il 11 agosto 2025 alle 8:30 AM ET per comunicare i risultati principali del suo studio pivotale di Fase 3 (IOB-013/KN-D18). Lo studio valuta Cylembio, un vaccino oncologico immunomodulatore sperimentale, in combinazione con KEYTRUDA® rispetto a KEYTRUDA® da sola nel trattamento di prima linea del melanoma avanzato.
Lo studio riguarda pazienti con melanoma non asportabile o metastatico; la direzione commenterà i risultati in diretta. Una registrazione sarà disponibile sul sito web della società dopo l’evento.
IO Biotech (NASDAQ:IOBT), compañía biofarmacéutica en fase clínica, ha programado una llamada de conferencia y un webcast para el 11 de agosto de 2025 a las 8:30 AM ET para dar a conocer los resultados principales de su ensayo pivotal de Fase 3 (IOB-013/KN-D18). El estudio evalúa Cylembio, una vacuna oncológica inmunomoduladora en investigación, en combinación con KEYTRUDA® frente a KEYTRUDA® sola para el tratamiento de primera línea del melanoma avanzado.
El estudio se centra en pacientes con melanoma irresecable o metastásico; la dirección realizará una presentación en vivo sobre los resultados. Después del evento, habrá una repetición disponible en la web de la compañía.
IO Biotech (NASDAQ:IOBT), 임상 단계의 바이오제약 회사가 2025년 8월 11일 오전 8시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 열어 주요 결과(톱라인)를 발표할 예정입니다. 이 중추적인 3상(Phase 3) 시험( IOB-013/KN-D18 )은 실험적 면역조절 암 백신인 Cylembio를 KEYTRUDA®와 병용한 경우와 KEYTRUDA® 단독을 비교해 진행성 흑색종의 1차 치료로서 평가합니다.
연구는 절제가 불가능하거나 전이성인 흑색종 환자를 대상으로 하며, 경영진이 결과를 실시간으로 설명합니다. 행사 후 회사 웹사이트에서 재청취(녹화본)를 제공할 예정입니다.
IO Biotech (NASDAQ:IOBT), société biopharmaceutique en phase clinique, a programmé une conférence téléphonique et un webcast pour le 11 août 2025 à 8h30 (ET) afin de communiquer les résultats principaux de son essai pivotal de Phase 3 (IOB-013/KN-D18). L’étude évalue Cylembio, un vaccin anticancéreux immunomodulateur en développement, en association avec KEYTRUDA® versus KEYTRUDA® seul en traitement de première intention du mélanome avancé.
L’étude porte sur des patients atteints d’un mélanome non résécable ou métastatique ; la direction présentera et discutera les résultats en direct. Un enregistrement sera disponible sur le site Web de la société après l’événement.
IO Biotech (NASDAQ:IOBT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklung, hat eine Telefonkonferenz und einen Webcast für den 11. August 2025 um 8:30 Uhr ET angesetzt, um die Topline-Ergebnisse seiner pivotalen Phase-3-Studie (IOB-013/KN-D18) vorzustellen. Die Studie untersucht Cylembio, einen experimentellen immunmodulierenden Krebsimpfstoff, in Kombination mit KEYTRUDA® gegenüber KEYTRUDA® allein als Erstlinientherapie beim fortgeschrittenen Melanom.
Untersucht werden Patienten mit nicht resektablem oder metastasiertem Melanom; die Geschäftsführung wird die Ergebnisse live diskutieren. Eine Aufzeichnung wird nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
08/10/2025 – 08:00 AM
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a biopharmaceutical firm specializing in cancer immunotherapy, announced today that it will be hosting a conference call and webcast to present the topline results from its pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) concerning its novel investigational therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant), in combination with pembrolizumab. The data will compare the efficacy of this combination therapy against pembrolizumab alone in first-line treatment for unresectable or metastatic (advanced) melanoma. The event is scheduled for Monday, August 11, 2025, at 8:30 AM ET.
Webcast and Conference Call Information
IO Biotech’s management team will host a combined webcast/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to deep-dive into the Phase 3 trial’s topline data regarding Cylembio. Interested parties can access the live webcast here or register in advance for the teleconference here. A complete replay of the webcast will be archived and made available on the IO Biotech corporate website following the live presentation.
About IO Biotech
IO Biotech is a biopharmaceutical company in the clinical phase, dedicated to pioneering the development of unique, immune-modulatory, off-the-shelf therapeutic cancer vaccines. These therapeutic candidates are built utilizing the company’s proprietary T-win® platform. The T-win platform revolves around an innovative approach to cancer vaccines, meticulously engineered to activate T cells. These activated T cells are designed to target both the malignant tumor cells and the immunosuppressive cells residing within the tumor microenvironment. IO Biotech is aggressively pursuing clinical trials for its leading cancer vaccine candidate, Cylembio®, coupled with the progression of additional pipeline candidates through pre-clinical development phases. Drawing strength from prior positive Phase 1/2 data in first-line metastatic melanoma, IO102-IO103, given in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been honored with a Breakthrough Therapy Designation from the US Food and Drug Administration for its potential impact on the treatment of advanced melanoma. IO Biotech maintains dual headquarters, with a base in Copenhagen, Denmark, and US headquarters situated in New York, New York.
For further information, please visit www.iobiotech.com. Stay connected through our social media channels on LinkedIn and X (@IOBiotech).
Contacts:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
[email protected]
Media
Julie Funesti
Edelman
917-498-1967
[email protected]
FAQ
When will IO Biotech (IOBT) announce Phase 3 trial results for Cylembio?
IO Biotech will announce the topline results during a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET.
What is the purpose of IO Biotech’s Phase 3 trial for Cylembio?
The Phase 3 trial evaluates Cylembio in combination with KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment for unresectable or metastatic melanoma.
What type of drug is IO Biotech’s Cylembio?
Cylembio (imsapepimut and etimupepimut, adjuvant) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine.
How can investors access IO Biotech’s Phase 3 results presentation?
Investors can access the live webcast or register for the teleconference through links provided by the company. A replay will be available on IO Biotech’s website after the event.
What is the trial identification number for IO Biotech’s Phase 3 Cylembio study?
The Phase 3 trial is identified as IOB-013/KN-D18 with the clinical trials registration number NCT05155254.
